首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >A Systematic, Integrated Study on the Neuroprotective Effects of Hydroxysafflor Yellow A Revealed byH1NMR-Based Metabonomics and the NF-κB Pathway
【24h】

A Systematic, Integrated Study on the Neuroprotective Effects of Hydroxysafflor Yellow A Revealed byH1NMR-Based Metabonomics and the NF-κB Pathway

机译:基于H1NMR的代谢组学和NF-κB通路揭示的羟基红花黄A的神经保护作用的系统,综合研究。

获取原文
           

摘要

Hydroxysafflor yellow A (HSYA) is the main active component of the Chinese herbCarthamus tinctoriusL.. Purified HSYA is used as a neuroprotective agent to prevent cerebral ischemia. Injectable safflor yellow (50 mg, containing 35 mg HSYA) is widely used to treat patients with ischemic cardiocerebrovascular disease. However, it is unknown how HSYA exerts a protective effect on cerebral ischemia at the molecular level. A systematical integrated study, including histopathological examination, neurological evaluation, blood-brain barrier (BBB), metabonomics, and the nuclear factor-κB (NF-κB) pathway, was applied to elucidate the pathophysiological mechanisms of HSYA neuroprotection at the molecular level. HSYA could travel across the BBB, significantly reducing the infarct volume and improving the neurological functions of rats with ischemia. Treatment with HSYA could lead to relative corrections of the impaired metabolic pathways through energy metabolism disruption, excitatory amino acid toxicity, oxidative stress, and membrane disruption revealed by1H NMR-based metabonomics. Meanwhile, HSYA treatment inhibits the NF-κB pathway via suppressing proinflammatory cytokine expression and p65 translocation and binding activity while upregulating an anti-inflammatory cytokine.
机译:羟基红花黄A(HSYA)是中草药Carthamus tinctoriusL的主要活性成分。纯净的HSYA被用作预防脑缺血的神经保护剂。注射用番红花黄(50μmg,含35μmgHSYA)被广泛用于治疗缺血性心脑血管疾病的患者。但是,尚不清楚HSYA如何在分子水平上对脑缺血发挥保护作用。进行了系统的综合研究,包括组织病理学检查,神经学评估,血脑屏障(BBB),代谢组学和核因子-κB(NF-κB)途径,从分子水平阐明了HSYA神经保护的病理生理机制。 HSYA可以穿越BBB,从而显着减少缺血大鼠的梗塞体积并改善其神经功能。 HSYA治疗可能通过能量代谢破坏,兴奋性氨基酸毒性,氧化应激和基于1 H NMR的代谢组学揭示的膜破坏,导致代谢途径受损的相对纠正。同时,HSYA治疗通过上调抗炎细胞因子同时抑制促炎细胞因子表达和p65易位和结合活性来抑制NF-κB途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号